Targets to trials in diabetic complications: Report on the satellite meeting to the international congress of physiological sciences "diabetic complications: Mechanisms underlying neuronal and vascular changes", 2-3 September, 2001, Melbourne, Australia

Drugs of Today

Volumn 37, Issue 11, 2001, Pages 739-748

  Doggrell, Sheila A ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 9 [(DIMETHYLAMINO)METHYL] 6,7,10,11 TETRAHYDRO 9H,18H 5,21; ALDOSE REDUCTASE INHIBITOR; ALPHA TOCOPHEROL; AMLODIPINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIOXIDANT; CONNECTIVE TISSUE GROWTH FACTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENKEPHALINASE INHIBITOR; GLUCOSE TRANSPORTER; INSULIN RECEPTOR SUBSTRATE 1; IRBESARTAN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NEPHRIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PROTEIN KINASE C; RAMIPRIL; ROSIGLITAZONE; RUBOXISTAURIN; SB 238063; SUPEROXIDE DISMUTASE; TRANSFORMING GROWTH FACTOR BETA; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASOPEPTIDASE INHIBITOR;

ATHEROSCLEROSIS; BLINDNESS; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; HEART INFARCTION; HUMAN; HYPERTENSION; IMPOTENCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LEG AMPUTATION; OXIDATIVE STRESS; REVIEW; STROKE; WOUND HEALING;

EID: 0035687430     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial
2. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial
3. 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years
4. 38: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes
5. Reduced coronary events in simvastatin-treated patient with coronary heart disease and diabetes or impaired fasting glucose levels: Subgroup analyses in the Scandinavian Simvastatin Survival Study
6. Mechanical stretch-induced fibronectin and transforming growth factor-β1 production in human mesangial cells is p38 mitogen-activated protein kinase-dependent
7. Hyperinsulinemia: The key feature of a cardiovascular and metabolic syndrome
8. Hypertension, hypertriglyceridemia, and impaired endothelium-dependent vascular relaxation in mice lacking insulin receptor substrate-1
9. Features of syndrome X develop in transgenic rats expression a non-insulin responsive phosphoenolpyruvate carboxykinase gene
10. An aldose reductase intragenic polymorphism associated with diabetic retinopathy
11. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor
12. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic rats
13. Regulation of inositol 1,4,5-trisphosphate receptors by transforming growth factor-β: Implications for vascular dysfunction in diabetes
14. Vitamin E supplementation improves endothelial function in type I diabetes mellitus: A randomized, placebo-controlled study
15. Retardation by amino-guanidine of development of albuminuria, mesangial expansion and tissue florescence in the streptozocin-induced diabetic rat
16. Aminoguanidine and ramipril prevent diabetes-induced increases in protein kinase C activity in glomeruli, retina and mesenteric artery
17. Effect of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
18. Vitamin E supplementation and cardiovascular events in high-risk patients
19. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy
20. The Irbesartan type II diabetic nephropathy trial: Study design and baseline patient characteristics
21. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
22. Effects of Iosartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy